NKTR Drug delivery Company | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
NKTR Drug delivery Company

An SI Board Since September 2005

Posts	SubjectMarks	Bans	Symbol
507	31	0	NKTR

Emcee: david nordic	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
157	Yahoos that got hold of a ML report on PFE today say 369 new prescriptions. Ain	tuck	-	10/10/2006
156	"I failed to sell calls against my shares before the "launch" and	Rocky9	-	10/8/2006
155	Although NKTR wins, this strikes me as a non-event. Nektar Therapeutics Issues	Ian@SI	-	10/3/2006
154	Well they do have one thing in common - both have a "k". No idea what	tom pope	-	9/29/2006
153	You had me going there. I thought AD had taken a firm hold. I really couldn&#	Ian@SI	-	9/29/2006
152	Sorry - wrong board!	tom pope	-	9/29/2006
151	Merrill: Reduced competitive risk for Sulonex Eli Lilly announced that the FDA	tom pope	-	9/29/2006
150	I suspect that the amount of competition will depend, in part, on how successful	Ian@SI	-	9/29/2006
149	>>Is the analyst distinguishing between introduction and rollout?<<	tuck	-	9/29/2006
148	Is the analyst distinguishing between introduction and rollout? or is something	Ian@SI	-	9/28/2006
147	One analyst likes NKTR... Nektar Therapeutics NKTR Miller Johnson From Marke	Ian@SI	-	9/28/2006
146	>>Zelos and Nektar Announce Start of Phase 1 Trial of Inhaled Ostabolin-C(	tuck	-	9/21/2006
145	Welllll! New CEO spent most of his time talking about PFEs drug program for Flor	Arthur Radley	-	9/20/2006
144	PFEs CEO is making presentation tomorrow..if no launch data..Exubera is history!	Arthur Radley	-	9/19/2006
143	"...the slow roll-out strategy. Not that I initially expected such a strate	technetium	-	9/19/2006
142	I assume the Amphotericin B will have a small market (hence the orphan drug stat	technetium	-	9/19/2006
141	This drug is one of a few to receive both US/Europe fast track/Orphan status Ne	david nordic	-	9/18/2006
140	Nektar's Amphotericin B Inhalation Powder (ABIP) Press Release Source: Nekt	david nordic	-	9/18/2006
139	All that is consistent with the slow roll-out strategy. Not that I initially ex	tuck	-	9/15/2006
138	My ardor for this stock gets colder and colder as I look at the info NKTR is tel	Arthur Radley	-	9/15/2006
137	>>Note that the holdings data I provided came from the WSJ/Thomson Financi	tuck	-	9/15/2006
136	Make sure the PR includes the purchase of a 6 month Prostate formulation that is	Ian@SI	-	9/15/2006
135	Do you suppose we could fake a PR about NKTR doing a tender offer? Cheers, Tuc	tuck	-	9/15/2006
134	Someone with a lot of shares has been reading this board and was spooked by the	DewDiligence_on_SI	-	9/15/2006
133	The reason for the sell-off is obvious. Answer in the next post…	DewDiligence_on_SI	-	9/15/2006

Go to reply# or date (mm/dd/yy):